[Clinical effects of beta-sitosterol (phytosterol) on benign prostatic hyperplasia: preliminary study]

Hinyokika Kiyo. 1998 Dec;44(12):865-8.
[Article in Japanese]

Abstract

Phytosterol derived from plants has long been used for the medical treatment of benign prostatic hyperplasia (BPH) in Europe but not in Japan. The efficacy of phytosterol was evaluated in patients with manifestations of urinary outlet obstruction caused by BPH. Phytosterol containing 180 mg of sitosterol per day was given to 12 patients with BPH in two or three divided doses for three months. The symptoms were assessed monthly using the International Prostate Symptom Score (IPSS) and quality-of-life (QOL) score while the objective findings including the urinary flow, prostatic volume, and residual urine volume were assessed after three months of treatment of BPH. The IPSS and QOL scores showed significant improvement (p < 0.05), and the peak flow rate and residual urine volume showed slight but not significant improvement.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Carboxylic Ester Hydrolases / chemistry
  • Carboxylic Ester Hydrolases / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Prostatic Hyperplasia / complications
  • Prostatic Hyperplasia / drug therapy*
  • Urination Disorders / drug therapy
  • Urination Disorders / etiology

Substances

  • Carboxylic Ester Hydrolases
  • phytosterol esterifying enzyme